Cheil Foods & Chemicals, Inc.

Korea Institute of Science and Technology

Yuhan Corporation

Korea Advanced Institute of Science and Technology

Choong S Kim

Jong Wook Lee

Je Hak Kim

Seung Ho An

Young Jun Shin

Il Hwan Cho

Yong Sik Youn

Ji Yoon Kang

Ki Hoon Lee

Jae Mok Lee

Jeong S Chae

Yeo H Yoon

Jin Woong Kim

Yang S Ahn

Chun S Lyu

Rok L Yun

Yong Hwan Jung

Jin Woo Lee

Jae Hong Lee

Chang Sik Kim

Jeong Woo Lee

Sung Yong Park

Kee Jeung Lee

Hong Sik Kim

Joong Heon Kim

Kwang Hee Lee

Sung Kwang Cho

Tae Song Kim

Nam Jin Lee

Seong Yeon Park

Bong Yong Lee

Nam Hee Lee

Byung Choul Kim

Hyune Soo Lee

Byung H Han

Jung J Suh

Yung B Chae

Jae Gwan Park

Young R Choi

Joung K Yoo

Ho Seong Yoo

Sung Shin Ryu

Kyoung E Choi

Koun H Lee

Yup Kang

Ji W Yoon

In Hye Lee

Kang Y Jung

Su Kyoung Chae

Keon H Lee

Ki Seok Cha

Hyune W Lee

Kang Sun Lee

The present invention relates to an apparatus and a method for fabricating a microcapsule, more particularly to an apparatus and a method for fabricating a microcapsule, which enable to encapsulate uniform cell number in a microcapsule through cell distribution, improve cell viability in the microcapsule through fluid exchange, and ensure uniform microcapsule size. The apparatus for fabricating a microcapsule according to the present invention uses a plurality of microchannels which are spatially connected with one another and are designed such that fluid flows through them in a particular direction, and comprises a cell supply unit which supplies a fluid mixture of cells and a cell dropletizing material; and a droplet forming unit in which a dropletization inducing fluid supplied from one of the plurality of microchannels joins with the fluid mixture of the cells and the cell dropletizing material to form a droplet.

Apparatus and method for fabricating micro-capsule

Disclosed is an apparatus and method for injecting liquid-drops of particle mixture liquid including a mixture of biological particles, affecting magnetic field, and having only positive particles, which are combined with magnetic responsive material, separated by magnetic force, and having negative particles, which are not combined with magnetic responsive material, precipitated by gravity.

Apparatus and method for separating biological particles using difference between gravity and magnetic force

The present invention provides a method of acylating organic amines using N,N'-diacylimidazolone derivatives represented by the general formula I as follows: ##STR1## wherein R.sub.1 and R.sub.2 are the same or different, which are selected from the group consisting of methyl, ethyl, straight or substituted aliphatic chain of C.sub.3 -C.sub.19, phenyl, heterocyclic groups, alkoxy and other organic acid substituting groups; and R.sub.3 and R.sub.4 are the same or different, which are selected from the group consisting hydrogen, methyl or ethyl, phenyl, substituted phenyl and alkoxycarbonyl, or wherein R.sub.3 and R.sub.4 form a R-substituted benzene ring having the following structure together with a carbon atom where R.sub.3 and R.sub.4 are bonded to: ##STR2## (wherein R is hydrogen, carboxyl or sulfonic groups).

Method of acylating amines using N,N'-diacylimidazolone derivatives

Pyridone carboxylic acid compounds and pharmaceutically acceptable salts and physiologically hydrolyzable esters thereof are provided which are represented by the formula: ##STR1## wherein R.sub.1 is a lower alkyl, a halogen-substituted lower alkyl, a lower alkenyl, a cycloalkyl, or a substituted- or unsubstituted-phenyl group; R.sub.2 is a hydrogen atom, or a lower alkyl or an amino group; A is a nitrogen atom or the group C--X wherein X is a hydrogen or a halogen atom, or an alkoxy group; and Z is a group having the formula: ##STR2## wherein n is 1 or 2; R.sub.3 and R.sub.4 each represent a hydrogen atom or a lower alkyl group, with proviso that, if n is 2, one of R.sub.3 and R.sub.4 is a hydrogen atom; R.sub.5 and R.sub.6 each represent a hydrogen atom, or a hydroxy, a lower alkoxy or an amino group which is unsubstituted or substituted by a lower alkyl group, with proviso that one of R.sub.5 and R.sub.6 is a hydrogen atom; and R.sub.7 is a hydrogen atom or a lower alkyl group. The compounds of the present invention show potent and broad spectrum of antibacterial activities.

Azabicyclic compounds useful as an intermediate for the preparation of

Pyridone carboxylic acid compounds or physiologically hydrolyzable esters thereof are provided which are represented by the formula: ##STR1## wherein R.sub.1 is a lower alkyl, a halogen-substituted lower alkyl, a lower alkenyl, a cycloalkyl, or a substituted- or unsubstituted-phenyl group; R.sub.2 is a hydrogen atom, or a lower alkyl or an amino group; A is a nitrogen atom or the group C-X wherein X is a hydrogen or a halogen atom, or an alkoxy group; and Z is a group having the formula: ##STR2## wherein n is 1 or 2; R.sub.3 and R.sub.4 each represent a hydrogen atom or a lower alkyl group, with proviso that, if n is 2, one of R.sub.3 and R.sub.4 is a hydrogen atom; R.sub.5 and R.sub.6 each represent a hydrogen atom, or a hydroxy, a lower alkoxy or an amino group which is unsubstituted or substituted by a lower alkyl group, with proviso that one of R.sub.5 and R.sub.6 is a hydrogen atom; and R.sub.7 is a hydrogen atom or a lower alkyl group. The compounds of the present invention show potent and broad spectrum of antibacterial activities.

Pyridone carboxylic acid compounds and their uses for treating

The specification describes a process for producing human proinsulin in Escherichia coli (E. coli) using gene manipulation technology. The process can provide for human proinsulin in high yields by a novel expression vector having strong regulatory elements of an insulin gene and a stable recombinant gene product. The expression vector of the present invention is characterized in that: 1) it has an 11 amino acid leader peptide containing six threonines in order to ensure an intracellular stability of proinsulin fusion protein, 2) it contains two copies of a DNA expression cassette each comprising a strong lambda P.sub.R promoter, a lac ribosome binding site, a proinsulin gene with a 17 amino acid leader peptide sequence containing a DNA sequence encoding (Thr).sub.6, and a strong fd phage transcription terminator (combination of phage fd terminator and translation stop codon), etc. successively ligated, 3) it has an ampicillin resistance gene, 4) it can be very stably retained within a cultured cell, and 5) there are a number of these expression vectors in E. coli by which the expression can be significantly increased. Human insulin is prepared from the proinsulin fusion protein by in vitro conversion.

Production of human proinsulin using a novel vector system

The present invention relates to novel cephem compounds having the formula: ##STR1## wherein, Q is a carbon or nitrogen atom; X is an oxygen atom, or a nitroalkyl or cyanoimine group, with the proviso that X cannot be an oxygen atom when Q is a carbon atom; R.sub.1 is a hydrogen atom, or a lower alkyl group, or a lower alkyl group which may be substituted by fluoro, or by a carboxylic group or an inorganic cation salt thereof; and R.sub.2 and R.sub.3 independently are a hydrogen atom or a lower alkyl group; or pharmaceutically acceptable salts thereof. The compounds of the present invention have potent antibacterial activities against gram-negative bacteria, especially Pseudomonas, and a longer half-life than conventional cephem compounds.

Cephem compounds

Novel semi-synthetic cephalosporin derivatives having a fused pyridiniummethyl at 3-position of the cephem nucleus, pharmaceutically acceptable salts, physiologically hydrolizable esters or solvates thereof are disclosed. Also disclosed is a process for preparing the cephalosporin derivatives which comprises introducing a fused pyridiniummethyl substituent at 3-position of 7-.beta.-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-cephem-ca rboxylic acid derivatives. The compounds of the present invention show potent antibacterial activities and a broad spectrum against both gram-positive and gram-negative bacteria.

3-fused pyridiniummethyl cephalosporins

2-(1,3-Dithiol-2-ylidene)-2-[N-(substituted) carbamoly] acetate esters and salts thereof, having potent therapeutic or prophylactic effect for hepatic disorder, are provided. Processes for their preparation and intermediates in their preparation also are disclosed.

1,3-dithiol-2-ylidene derivatives and process for the preparation thereof

2-(1,3-Dithietan-2-ylidene)-2-[N-(subsittuted)carbamoyl]acetate esters and 2-(1,3-dithiolan-2-ylidene)-2-[N-(substituted) carbamoyl]acetate esters, having potent therapeutic and prophylactic effect for hepatic disorders, are provided.

Dithioketene derivatives, pharmaceutical compositions containing the

The present invention relates to 1,4-dihydropyridine of the formula(I) ##STR1## wherein R.sup.1 represents a phenyl group which may be substituted by one or two substituents selected from halogeno, nitro, trifluoromethyl and difluoromethoxy group, or 2,1,3-benzoxadiazole-4-yl group, R.sup.2 represents a lower alkyl or phenyl group, R.sup.3 represents a lower alkyl group and Y represents an oxygen or sulfur atom. The compounds of the formula(I) can be employed for treatment or prevention of cardiovascular diseases.

Dihydropyridine derivatives

This invention discloses a process for the preparation of (.+-.)-4-oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinoline derivatives which comprises conducting an intramolecular cyclization reaction of the compounds of formulas II III in an acid medium. ##STR1##

Process for the production of

This invention discloses a process for the production of hydroxymethylimidazoles which comprises reacting imidazolecarboxylic acids, their esters or inorganic salts with a formaldehyde agent in the presence of an alkali in an aqueous medium.

Process for the production of hydroxymethylimidazoles

Growing community of inventors

Seoul, South Korea

Choong S Kim